|Dr Tariq Ahmad is a Consultant Gastroenterologist at the Royal Devon and Exeter NHS Foundation Trust, Lead Clinician for the Exeter Inflammatory Bowel Disease (IBD) Service and Honorary Associate Professor at the University of Exeter Medical School. He is the elected UK representative of the European Crohn’s and Colitis Organisation, medical advisor to Crohn’s & Colitis UK and a member of the NHS England and Genomics England Joint Pharmacogenomics Working Group.
Dr Ahmad studied medicine at the University of Bristol and obtained a doctorate from the University of Oxford on the genetics of IBD. Dr Ahmad integrates translational research and clinical trials with clinical practice. The Exeter IBD research group focusses on the development and implementation of genetic and serological tests to allow individualised treatment strategies for patients with IBD. Dr Ahmad is the chief investigator of PRED4 (www.ibdresearch.co.uk) which has led to actionable pharmacogenetic findings, and PANTS (https://pantsdb.co.uk) which has driven the rapid adoption of biologic monitoring into UK practice. Dr Ahmad has been awarded numerous research grants and has published widely in major peer-reviewed journals.
|Palle Bager is clinical nurse specialist & senior researcher at Department of Hepatology and Gastroenterology at Aarhus University Hospital and associate professor at Aarhus University, Denmark.
He became a Registered Nurse in 1987, added a Diploma in Health Education in 2002, Master of Public Health in 2007 and a PhD degree in 2014.
The topic of his PhD was 'Anaemia and fatigue in patients with IBD or upper GI bleeding'. Anaemia and fatigue are still in focus in his research. Other topics include: IBD nursing, patient participation, outpatient services and health economics.
Dr. Bager has been active in the European Crohn's and Colitis Organisation (ECCO) for several years. Currently he is chair of N-ECCO (Nurses-ECCO).
|Jakob Benedict Seidelin|
|Christianne Buskens graduated at the Medical School at the University of Utrecht in 1999. From 2000 until 2003 she worked as a research fellow at the department of surgery, and the department of experimental oncology at the Academic Medical Centre (AMC) in Amsterdam. This resulted in her PhD thesis ´The development of new treatment strategies for oesophageal cancer’, which she defended with distinction in 2004. She was trained as a surgeon from 2003 until 2009 at the AMC, Antoni van Leeuwenhoek Hospital (Amsterdam), and Gelre Hospitals (Apeldoorn). After completion of her surgical training, she was granted a fellowship from the Dutch Cancer Organization (KWF) at the department of colorectal surgery in Oxford, United Kingdom. Here, she specialized in proctology and minimally invasive surgery. In January 2012, she became a staff member of the AMC colorectal surgeons group. Nowadays, she combines her clinical work as an IBD surgeon with translational research which is funded by an innovative research incentive grant from The Netherlands organisation for health research and development. Her research lines focus on the role of the appendix in ulcerative colitis, and the the effector functions of (myeloid) immune cells. She also has a masters in clinical epidemiology.|
Anthony de Buck van Overstraeten
|Anthony de Buck van Overstraeten obtained his medical degree at the University of Leuven in Belgium, where he completed his surgical and colorectal training. In 2013 he completed a colorectal fellowship at Mount Sinai Hospital in Toronto. He then returned to Belgium and after 4 years as a colorectal surgeon at the University Hospital of Leuven in Belgium, he moved to Toronto in 2017 where he is an Assistant Professor in the Department of Surgery at the University of Toronto, and a colorectal surgeon in the Department of Surgery at Mount Sinai Hospital. He has a Master’s Degree in Clinical Epidemiology from the University of Toronto. His scientific work focusses on clinical outcome research, mainly situated in the field of IBD, and specifically focussing on functional and quality of life outcomes in IBD patients, including the impact of minimally invasive surgery on clinical outcome.|
|Michael Eberhardson has a Medical Degree (MD) and a PhD (in Medical Cell Biology) from Uppsala University and is Associate Professor in Gastroenterology at Karolinska Institutet. He is a consultant in Gastroenterology with focus on IBD and medical lead of the Gastro Research Unit at Danderyd Hospital. He also serves part time at the Department of Clinical Immunology, Karolinska University Hospital. Dr Eberhardson has a special interest in immunological monitoring of IBD. He is a member of the board of the Swedish Organisation for the Study of IBD (SOIBD) and a member of the steering committee of the National Quality Registry for Inflammatory Bowel Disease (SWIBREG). He is elected national representative of the European Crohn’s and Colitis Organisation (ECCO).|
|Martti Färkkilä is a professor of gastroenterology at Helsinki University and head of Clinic of Gastroenterology at Helsinki University Hospital (HUH). His main interests are treatment of viral hepatitis, cholestatic liver diseases, especially PSC and inflammatory bowel disease. He has been responsible for the treatment guidelines for HCV and HBV at HUCH. He has supervised 15 PhD students and published more than 220 orginal papers.|
|Jonas Halfvarson is a Consultant Gastroenterologist specialising in IBD at Örebro University Hospital, Sweden. He graduated as MD at Uppsala University, Sweden, before training in gastroenterology at Örebro University Hospital. He undertook research with Professor Gunnar Järnerot and obtained his PhD, entitled ‘Inflammatory bowel disease in twins; Studies of genetics and environmental factors’ in 2004. Part of his PhD was done at the University of Oxford, UK with Professor Derek Jewell. Today his research focuses on biomarkers in IBD, both from a clinical and from a mechanistic perspective. He has published over 60 peer-reviewed full papers, as well as contributed to several books on IBD. He has served as vice director for the Swedish national PhD and Postdoctoral program for translational gastroenterology and heads the taskforce for genetics and pathophysiology at the Swedish Organisation for the Study of IBD. Today he is appointed Associate Professor at Örebro University and combines his time in clinical practice with his positions at the University. Dr Halfvarson was named a Rising Star in Gastroenterology at the United European Gastroenterology (UEGWeek) in 2011 and is a member of the International Organization for the study of Inflammatory Bowel Disease (IOIBD) since 2014.|
|Randi Opheim is senior researcher and advanced nurse specialist at Department of Gastroenterology, Oslo University Hospital and Associate professor at Institute of Health and Society, University of Oslo, Norway. She has a PhD from 2014 in clinical epidemiology, including use of complementary therapies in patients with inflammatory bowel disease. Today her research is focusing on clinical epidemiology, psychosocial health, symptom burden, and health- care research. She is member of the steering committee in the IBSEN III study - a large population based prospective study of newly diagnosed patients with inflammatory bowel disease. She combines clinical work and academic profession, lecturing and supervision.|
|Dr Tim Raine MB, BChir, PhD
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Tim Raine is a consultant gastroenterologist at Addenbrooke’s Hospital, Cambridge, UK, where he leads the inflammatory bowel disease (IBD) service.
Tim has an active interest in human clinical trials in IBD and has worked as a chief investigator/principal investigator on a number of preclinical and clinical trials in IBD therapeutics, including first-in-human studies. He is the lead investigator for the major UK IASO trial in acute severe colitis. He is a member of the European Crohn’s and Colitis Organisation (ECCO) and sits on the ECCO guidelines committee; he is an author of several current ECCO guidelines and a project leader for the both Crohn’s and UC guidelines currently in development. He serves on the British Society of Gastroenterology (BSG) IBD Clinical Research Group, was awarded the BSG Young Gastroenterologist of the Year Award 2016, and is a group leader for the BSG IBD guidelines group.
He is an honorary faculty member of the Wellcome Trust Sanger Institute, Hinxton, UK. His research, funded by the Wellcome Trust, CCFA and the UK National Institute for Health Research (NIHR), focuses on understanding the regulation of the gastrointestinal immune system, in particular the immunological basis for genetic risk in IBD.
1999 – Student at Birkerød Gymnasium
2007 – Medical Doctor (MD) at University of Copenhagen
2009 – Medical authorization
2013 – PhD at Faculty of Health and Medical Sciences at the University of Copenhagen
2016 – Doctor of Medical Science (DMSc) at the University of Copenhagen
2007-9 – Medical and surgical rotation at Holbæk Hospital and general practice in Nkb. Sjælland
2009-12 – PhD at Dept. of Gastroenterology, Medical Section, Herlev Hospital
2012 – Dept. of Dermatology, Gentofte Hospital
2013 – Dept. of Internal Medicine, Gentofte Hospital
2013 – Postdoc at Dept. of Gastroenterology, Herlev Hospital
2014 – Dept. of Gatsroenterology, Herlev Hospoital
2014- – Resident in Internal Medicine: Gastroenterology & Hepatology (Glostrup/Riget/Herlev)
2015 – Postdoc at Dept. of Gastroenterology, Herlev Hospital